

APOC1 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP2770c

Specification

APOC1 Antibody (Center) Blocking Peptide - Product Information

Primary Accession P02654

APOC1 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 341

Other Names

Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, Truncated apolipoprotein C-I, APOC1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP2770c was selected from the Center region of human APOC1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APOC1 Antibody (Center) Blocking Peptide - Protein Information


Name APOC1

APOC1 Antibody (Center) Blocking Peptide - Background

APOC1 is a member of the apolipoprotein C1 family. This protein is expressed primarily in the liver, and it is activated when monocytes differentiate into macrophages.

APOC1 Antibody (Center) Blocking Peptide - References

Bahri,R., Lipids Health Dis 7 (1), 46 (2008)Meunier,J.C., J. Virol. 82 (19), 9647-9656 (2008)Nagelkerken,L., J. Invest. Dermatol. 128 (5), 1165-1172 (2008)





Function

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

Cellular Location Secreted.

Tissue Location

Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen

APOC1 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides